Progress in the treatment of Friedreich ataxia

Publication date: March 2018Source: Neurologia i Neurochirurgia Polska, Volume 52, Issue 2Author(s): Geneieve Tai, Louise A. Corben, Eppie M. Yiu, Sarah C. Milne, Martin B. DelatyckiAbstractFriedreich ataxia (FRDA) is a progressive neurological disorder affecting approximately 1 in 29,000 individuals of European descent. At present, there is no approved pharmacological treatment for this condition however research into treatment of FRDA has advanced considerably over the last two decades since the genetic cause was identified. Current proposed treatment strategies include decreasing oxidative stress, increasing cellular frataxin, improving mitochondrial function as well as modulating frataxin controlled metabolic pathways. Genetic and cell based therapies also hold great promise. Finally, physical therapies are being explored as a means of maximising function in those affected by FRDA.
Source: Polish Journal of Neurology and Neurosurgery - Category: Neurosurgery Source Type: research